– USA, NY – Intrance Medical Systems Inc., a subsidiary of Sweden-based Intrance Holdings AB, today announced the completion of its final Series A financing round totaling $17m.
Internationally well renowned Scandinavian investors, Erik Selin and Rutger Arnhult participated in the financing as anchor investors.
Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, a fixed-dose combination treatment of carbidopa, entacapone, and levodopa for enteral infusion in advanced Parkinson’s disease patients.
Concurrent with the financing, Intrance announced the appointment of Ed Schutter to the Board of Directors. Mr. Schutter, who most recently served as CEO of Arbor Pharmaceuticals, is also a shareholder in the company and becomes Intrance’s first U.S.-based board member.
“Completion of this funding round represents a significant accomplishment for Intrance and brings us one step closer to ensuring our innovative drug-device therapy reaches patients with advanced Parkinson’s disease in the U.S.,” said Ulf Rosén, Chairman of the Board and Co-founder of Intrance Medical Systems. “The addition of Ed to our board comes at a critical time in our company’s growth. His unparalleled expertise and strong corporate strategy, business development, and executive management experience further strengthens our board and will prove to be extremely valuable as we execute upon several key clinical and regulatory milestones in the U.S.”
“I am delighted to welcome Ed to our board, and I look forward to working with him and benefiting from his wealth of industry experience,” said Patrick Shea, CEO Intrance Medical Systems. “We also greatly appreciate the support by our investors who recognize the value we have created since our initial funding and the potential of our asset to improve the lives of patients with advanced Parkinson’s disease.”
About Ed Schutter
Prior to Arbor, Ed Schutter served as President of Sciele (Shionogi) Pharmaceuticals. Previously, he served as VP of Global Business Development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. Mr. Schutter began his pharmaceutical career with Reid-Provident Labs, a small entrepreneurial pharmaceutical company based in Atlanta, GA.
“I am honored to join Intrance’s board and help shape the formation of the company’s U.S. corporate and commercial strategy,” said Mr. Schutter. “This is truly an exciting time for Intrance, which is well-positioned to become a leading player in the space with an innovative solution that has the potential to significantly improve the quality of life and outcomes for patients with advanced Parkinson’s disease. I am extremely impressed with the team and commercial success of Intrance’s product in Europe.”
Mr. Schutter is a registered pharmacist with a B.S. in Pharmaceutical Sciences from Mercer University and an MBA from Kennesaw State University. In addition, he completed graduate studies in International Business at Njienrode University, Amsterdam, Netherlands. He currently serves on the boards of directors of several public and private companies and has been a previous board member for several non-profit organizations, including the American Diabetes Association and American Heart Association.
About Intrance Medical Systems
Intrance Medical Systems, Inc., a subsidiary of Sweden-based Intrance Holdings AB, is a private biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan, and Taiwan. Intrance’s lead product, known as Lecigon in the Nordic countries and certain European markets, is a fixed-dose combination treatment of levodopa, carbidopa, and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is planning to advance its U.S. clinical development program in this target indication and recently filed an Investigational New Drug application with the U.S. Food and Drug Administration.
For more information: https://www.intrancemedical.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.